ClinicoEconomics and Outcomes Research最新文献

{"title":"The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia.","authors":"Nada Abu-Shraie, Afaf Al-Sheikh, Ibtisam Alharbi, Layla Alanizy, Mohammed Alshraim, Sahal I Khoshhal, Sarah A AlSalman, Ali Alrumaih, Ahmad Nader Fasseeh, Baher Elezbawy, Nada Abaza, Amr Semida, Marina George, Shireen Amin, Yousef Binamer","doi":"10.2147/CEOR.S604093","DOIUrl":"10.2147/CEOR.S604093","url":null,"abstract":"<p><strong>Objective: </strong>Atopic dermatitis (AD) is a prevalent dermatological disease in Saudi Arabia. This study aimed to estimate the cost-effectiveness and budget impact of upadacitinib in adults and adolescents with moderate-to-severe AD in Saudi Arabia.</p><p><strong>Methods: </strong>A 1-year decision tree model followed by a lifetime Markov model was developed to estimate the cost-effectiveness of upadacitinib compared to dupilumab and other novel AD treatments in moderate-to-severe AD patients aged ≥12 years in Saudi Arabia from the public payer perspective. In addition, we developed a 5-year budget impact model to estimate the financial consequences of increasing the market share of upadacitinib. Probabilistic and deterministic sensitivity analyses were conducted to test the model's robustness.</p><p><strong>Results: </strong>Over a lifetime horizon, upadacitinib 15 mg was associated with 0.21 additional quality-adjusted life years (QALYs) and lower costs by 148,068 SAR (39,484 USD) compared with dupilumab 300 mg. The net monetary benefit of upadacitinib 15 mg versus dupilumab 300 mg was 158,656 SAR (42,308 USD). For the budget impact, increasing the market share of upadacitinib over 5 years was associated with estimated savings of 1.5 billion SAR (412 million USD). Sensitivity analyses results supported the direction of the base-case findings.</p><p><strong>Conclusion: </strong>Upadacitinib may be a cost-effective treatment for moderate-to-severe AD in Saudi Arabia. Increasing its market share could be considered for the target population and may reduce public healthcare costs over 5 years. However, these model-based estimates should be interpreted with uncertainty due to input assumptions and local data limitations.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"604093"},"PeriodicalIF":2.6,"publicationDate":"2026-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13271258/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148273371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States.","authors":"Neal Shore, Benjamin Lowentritt, Charmi Patel, Sabree Burbage, Frederic Kinkead, Carmine Rossi, Francesca Lee, Dominic Pilon, Lawrence Karsh, Gordon Brown","doi":"10.2147/CEOR.S590934","DOIUrl":"10.2147/CEOR.S590934","url":null,"abstract":"<p><strong>Background: </strong>Radical prostatectomy is a potentially curative treatment for localized prostate cancer (LPC), but there is limited literature comprehensively describing clinical and economic outcomes stratified by risk group. This study compared survival and healthcare costs following radical prostatectomy between patients with high-risk and low/intermediate-risk LPC in routine urology practice in the US.</p><p><strong>Methods: </strong>Linked electronic medical records and administrative claims were used to identify men with LPC undergoing radical prostatectomy (index date). Patients were classified into high-risk or low/intermediate-risk cohorts based on staging, prostate-specific antigen test results, and Gleason score, in alignment with the National Comprehensive Cancer Network^®. Cohorts were balanced using inverse probability of treatment weighting. Metastasis-free survival and event-free survival post index were compared between cohorts using a weighted Cox proportional hazards model. All-cause/prostate cancer (PC)-related healthcare costs were compared post index using weighted ordinary least squares regression in a subgroup of patients with 12 months of continuous insurance eligibility prior to/including index.</p><p><strong>Results: </strong>Patients in the high-risk cohort (N=7542) had significantly higher rates of metastasis (36 months: hazard ratio [95% confidence interval (CI)]: 3.80 [3.31, 4.38], p<0.001; 60 months: 3.59 [3.19, 4.04], p<0.001) and disease progression (36 months: 3.49 [3.28, 3.71], p<0.001; 60 months: 3.37 [3.18, 3.57], p<0.001) compared to patients in the low/intermediate-risk cohort (N=11,429). In the cost subgroup, the high-risk cohort (N=1488) incurred significantly higher mean total all-cause healthcare costs (cost difference [95% CI]: $9134 [5999, 12,400] per-patient-per-year, p<0.001) and mean total PC-related healthcare costs ($7502 [4718, 10,279] per-patient-per-year, p<0.001) compared to the low/intermediate-risk cohort (N=2572) post index.</p><p><strong>Conclusion: </strong>In this real-world analysis of patients with LPC who underwent radical prostatectomy, high-risk disease was significantly associated with poorer survival and higher healthcare costs post-procedure compared to low/intermediate-risk LPC. These findings demonstrate the heightened clinical and economic burden observed with high-risk LPC.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"590934"},"PeriodicalIF":2.6,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222597/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148145011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Medication Consumptions in Vietnam Between 2019 and 2023: An Analysis from the National Database.","authors":"Mai Thi Tuyet Kieu, Duc Quang Tran, Anh Thi Phuong Le, Ha Thi Nguyen, Minh Cong Nguyen","doi":"10.2147/CEOR.S604685","DOIUrl":"10.2147/CEOR.S604685","url":null,"abstract":"<p><strong>Purpose: </strong>This study was conducted to analyse cancer medication consumption in Vietnam between 2019 and 2023.</p><p><strong>Materials and methods: </strong>This was a cross-sectional study using data of cancer medication consumption that was publicly announced by Drug Administration of Vietnam (DAV) as a proxy. Data on expenditures and purchasing characteristics were extracted from every bidding package and contract implemented throughout the period. They afterwards were quantified and categorised by bidding technical groups, chemical classes, procurement levels, manufacturing origins and administration routes. Descriptive and statistical analyses were performed to explore the relationship between consumption, price and bidding mechanisms.</p><p><strong>Results: </strong>The total consumption of cancer medications between 2019 and 2023 in Vietnam was estimated to be about $1.4 billion. Of which the number slightly increased in 2020 before dropping sharply to 2022 and finally rebounding and reaching its peak in 2023 with $359.5 million. Targeted therapies consistently accounted for the largest proportion (44-48%), followed by chemotherapies with 34-39% and immunotherapies with 8-16%. Most expenditures were attributed to originator products and high-quality generics (Group 1), contributing 73-85% annually. Overall, the mean price per milligram decreased over time, with notable variation driven by shifts in the distribution of bidding technical groups while the centralized national-bidding was generally more efficient than regional procurements.</p><p><strong>Conclusion: </strong>Cancer medication consumption in Vietnam fluctuated substantially between 2019 and 2023, accompanied by significant changes in procurement patterns and the pandemic. Strengthened and targeted policies are required to optimize the economic impact of this group of medication, while broader efforts are needed to alleviate the cancer burden in Vietnam.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"604685"},"PeriodicalIF":2.6,"publicationDate":"2026-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148144962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Model-Based Cost-Effectiveness Analysis of Routine Omega-3 Testing and Targeted Supplementation to Reduce Early Preterm Birth in Australia Compared with Current Practice.","authors":"Hossein Haji Ali Afzali, Ecushla Linedale, Craig Martin, Muktar Ahmed, Julie Quinlivan, Andrew J McPhee, Penelope Coates, Lucas Semmler, David Cox, Robert Alan Gibson, Maria Makrides, Karen P Best","doi":"10.2147/CEOR.S585692","DOIUrl":"10.2147/CEOR.S585692","url":null,"abstract":"<p><strong>Background: </strong>Preterm birth remains a leading cause of newborn death, disability, and long-term health challenges globally, with a substantial impact on families, the health system, and society. Omega-3 supplementation in women with low omega-3 status in early pregnancy has been shown to reduce the risk of preterm birth, particularly early preterm birth (<34 weeks of gestation). The cost implications of incorporating omega-3 testing and targeted supplementation into routine antenatal care to reduce early preterm birth in Australia are unclear.</p><p><strong>Methods: </strong>A decision analytic model was developed using Australian epidemiological, clinical, and cost data to compare routine omega-3 testing and targeted supplementation with current practice. The model predicted the number of early preterm births prevented and associated cost savings over an 18-year time horizon. Deterministic sensitivity analyses were conducted to examine uncertainty in key model inputs.</p><p><strong>Results: </strong>Among 289,195 singleton pregnancies in 2022, an estimated 17.5% of women would have low omega-3 status and be eligible for supplementation. Making conservative assumptions, the model predicted that, relative to current practice, omega-3 testing and supplementation would be a dominant strategy, preventing 640 early preterm births, with projected savings of $26.1 million in direct healthcare costs. Sensitivity analyses indicated that the results were robust across most scenarios and identified the treatment effect estimate as the strongest driver of model predictions.</p><p><strong>Conclusion: </strong>Omega-3 testing in early pregnancy with targeted supplementation may offer a scalable and cost-effective strategy to reduce early preterm birth with potential benefits for mothers, infants, and the health system. The modelling suggests meaningful health and economic benefits. Cost savings were robust across most plausible scenarios, supporting the potential value of this approach on a national scale.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"585692"},"PeriodicalIF":2.6,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148139327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Socioeconomic Impact of Long-Acting Injectable Buprenorphine.","authors":"Samuel E Rasche, George O W Batchelor, Catharine Montgomery, Harry R Sumnall, Daniel Mogford","doi":"10.2147/CEOR.S590462","DOIUrl":"10.2147/CEOR.S590462","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the socioeconomic impact of increased uptake of long-acting injectable buprenorphine (LAIB) for opioid use disorder (OUD) in England.</p><p><strong>Materials and methods: </strong>A cost-benefit analysis was conducted from a societal perspective over a one-year time horizon. An economic model compared existing standard of care for OUD with a scenario in which a proportion of individuals switched to LAIB and additional individuals not currently in treatment initiated care with LAIB, based on uptake and retention assumptions. Areas of impact (e.g., crime, healthcare, and employment) were identified and quantified using a targeted literature review and published unit cost estimates.</p><p><strong>Results: </strong>Assuming approximately 30,000 people could receive LAIB, the annual cost is estimated at £77 million, while the projected benefits total £236 million, resulting in a benefit-cost ratio of 3.1. The greatest savings are expected to be derived from reductions in crime and incarceration, followed by socioeconomic gains through increased employment, improved quality of life, prevented fatalities, decreased healthcare burden, and reduced social care costs.</p><p><strong>Conclusion: </strong>Despite higher acquisition costs than current standard treatments, LAIB was estimated to be cost-beneficial, with potential to improve outcomes for individuals while generating substantial value for society.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"590462"},"PeriodicalIF":2.6,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13199596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148036332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis.","authors":"Biao Li, Jingjing Yang, Jing Li, Jiajia Huang, Zhiming Li","doi":"10.2147/CEOR.S590836","DOIUrl":"10.2147/CEOR.S590836","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the cost-effectiveness of nivolumab plus doxorubicin/vinblastine/dacarbazine (N-AVD) versus brentuximab vedotin-AVD (BV-AVD) as first-line treatment for advanced-stage classical Hodgkin lymphoma.</p><p><strong>Design: </strong>Cost-effectiveness analysis using a Markov model based on the S1826 trial (n=970). We estimated total direct costs, life-years (LYs), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICER). Sensitivity analyses assessed robustness.</p><p><strong>Results: </strong>Nivolumab-AVD yielded 6.560 QALYs and 15.659 LYs, representing gains of 0.504 QALYs and 0.551 LYs over Brentuximab vedotin-AVD. Total costs were $784,839 for Nivolumab-AVD compared with $789,205 for Brentuximab vedotin-AVD. Nivolumab-AVD was associated with negative incremental cost-effectiveness ratios (-$8,656 per QALY; -$7,926 per LY) and was dominant, offering superior health outcomes at a lower overall cost.</p><p><strong>Conclusion: </strong>From a Chinese healthcare payer perspective, nivolumab-AVD is more cost-effective than brentuximab vedotin-AVD for advanced-stage classical Hodgkin lymphoma, offering lower costs and better health outcomes.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"590836"},"PeriodicalIF":2.6,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13199610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148036374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy.","authors":"Donatella Panatto, Marco Bellone, Luca Castello, Laura Zanetta, Alberto Piccolo","doi":"10.2147/CEOR.S588333","DOIUrl":"10.2147/CEOR.S588333","url":null,"abstract":"<p><strong>Purpose: </strong>Influenza is a significant public health concern, particularly among the elderly, contributing to high morbidity, hospitalizations, and mortality, in addition to increased economic burden sustained by the Italian National Health Service (SSN). Traditional vaccines, ie, standard-dose trivalent inactivated influenza vaccine (TIV-SD), showed lower immunogenicity and effectiveness in older adults than in younger adults, as a result of the immunosenescence process and increased comorbidities. Enhanced formulations, such as the high-dose trivalent influenza vaccine (TIV-HD), have been introduced to address this gap. This study evaluates the cost-effectiveness of TIV-HD compared to TIV-SD for individuals ≥65 years of age in Italy.</p><p><strong>Patients and methods: </strong>A cost-effectiveness analysis was performed using a population-based decision-analytic model from the perspective of the SSN, over a one-year time horizon. The model simulated clinical pathways for influenza-related events, including general practitioner visits, emergency department consultations, hospitalizations for cardiorespiratory complications, and mortality. Epidemiological and cost data were sourced from national databases and peer-reviewed literature. Three pricing scenarios were explored. The outcomes included life-years (LYs), quality-adjusted life years (QALYs), and healthcare costs, allowing the calculation of the incremental cost-effectiveness ratio (ICER).</p><p><strong>Results: </strong>Model-based results showed that TIV-HD is a dominant strategy over TIV-SD, yielding both improved health outcomes (14,070 LYs and 13,678 QALYs) and cost savings in all the pricing scenarios explored. When applied to the Italian elderly population eligible for seasonal influenza vaccination, TIV-HD was estimated to generate overall savings ranging from €82.3 million and €135.0 million for the National Health Service, driven by the prevention of approximately 50,000 influenza-related hospitalizations.</p><p><strong>Conclusion: </strong>This analysis indicates that TIV-HD was associated with improved outcomes and lower overall costs compared with TIV-SD under the modeled assumptions. The enhanced clinical effectiveness combined with significant cost reductions underscores TIV-HD as a cost-effective intervention, contributing to sustainable healthcare management in Italy.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"588333"},"PeriodicalIF":2.6,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13175930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147965192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research Gaps and Priorities for aHUS in the Gulf Cooperation Countries (GCC): Findings from a Payer-Focused Expert Meeting.","authors":"Laila Carolina Abu Esba, Ghada Hussain AlMardawi, Abdulaziz Alhenaidi, Mohamed Ahmed, Abdullah O AlShehry, Waiel Al Naeem, Qasim Alshara, Omar Alkandari, Hussain Abdulrahman Al-Omar","doi":"10.2147/CEOR.S595064","DOIUrl":"10.2147/CEOR.S595064","url":null,"abstract":"<p><p>Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening complement-mediated thrombotic microangiopathy (TMA) associated with high morbidity, mortality, and substantial healthcare resource utilization (HCRU). Although complement inhibitors such as eculizumab and ravulizumab have dramatically improved outcomes, aHUS continues to impose significant economic and operational burden on healthcare systems. In the Gulf region, payers and health systems face increasing pressures driven by rising costs, delayed diagnosis, fragmented access, and limited real-world evidence necessary for informed resource allocation decisions. This manuscript summarizes the findings of a payer-focused regional expert meeting, which included three presentations: (1) the role and value of HCRU studies for payers, (2) the clinical and economic burden of aHUS, and (3) existing global evidence on HCRU in aHUS and gaps relevant to the Gulf. The meeting concluded with an expert panel discussion and a survey assessing feasibility and priorities for a collaborative real-world study. Consensus highlighted urgent needs to establish regional incidence and prevalence, quantify utilization and cost burden, evaluate treatment patterns and outcomes, and design a standardized multicenter study. Priority research directions include retrospective chart review with prospective follow-up and unified data collection across Gulf institutions. These findings provide a payer-informed roadmap for building evidence that can support sustainable, equitable, and value-based decision making for aHUS care in the region.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"595064"},"PeriodicalIF":2.6,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13158029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147934563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness of Chondroitin Sulphate (with or without Glucosamine) Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs.","authors":"Carlos Rubio-Terrés, Miguel Bernad Pineda, Josep Vergés","doi":"10.2147/CEOR.S577731","DOIUrl":"10.2147/CEOR.S577731","url":null,"abstract":"<p><strong>Background: </strong>Chondroitin sulfate, alone or associated with glucosamine (CS/CS+GLU), is an effective knee osteoarthritis (KOA) treatment, with fewer adverse effects (AEs) than non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase 2 inhibitors (COXIBs).</p><p><strong>Purpose: </strong>To estimate the CS/CS+GLU cost-effectiveness versus NSAIDs/COXIBs, due to the avoidance of mild-moderate or severe gastrointestinal AEs (GIAE), ischemic heart disease (IHD), acute kidney insufficiency (AKI), chronic kidney failure (CKF) and ischemic stroke (IS) from the Spanish National Health System (NHS) perspective.</p><p><strong>Methods: </strong>Two analyses were considered: 1) savings to the NHS from current CS/CS+GLU treatment; and 2) maximum savings that could be achieved by the NHS if all patients with KOA currently treated with NSAIDs/COXIB would be switched to CS/CS+GLU. AEs frequency, associated utilities loss and managing cost were obtained from medical literature and Spanish sources. A probabilistic model (second-order Monte Carlo simulation) was carried out for a 3-year time horizon. Treatment duration: 180 days (base case); 90 and 240 days (sensitivity analysis).</p><p><strong>Results: </strong>First analysis: 45,087 mild-moderate GIAE, 3,217 severe GIAE, 211 IHD, 1,087 AKI, 746 CKF and 3,359 IS, would be avoided with CS/CS+GLU. Discounting drugs cost, the three-year savings would be 57.1 million euros (savings probability: 80.7%). The savings per patient treated with CS/CS+GLU would amount to €38.02 (95% CI 14.06; €75.69), with a mean gain of 0.0023 (95% CI 0.0018-0.0027) QALY. The probability that CS/CS+GLU treatment was dominant (lower costs and QALY gain) or cost-effective (cost per QALY gained less than €25,000) was 80.7% and 98.1%, respectively. In the second analysis, savings for the NHS would amount to 387 million euros, with the CS/CS+GLU-only option being dominant and cost-effective in 100% of the analyses.</p><p><strong>Conclusion: </strong>The improved tolerability of CS/CS+GLU versus NSAIDs/COXIBs is expected to prevent thousands of AEs and generate considerable savings for the NHS, making it cost-effective treatment.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"577731"},"PeriodicalIF":2.6,"publicationDate":"2026-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147876034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Burden of Overall and Advanced Light Chain Amyloidosis: Results from a Claims Linked Electronic Health Record Database Analysis.","authors":"Jeffrey A Thompson, Ankita Gupta, Julia Catini, Pedro A Laires","doi":"10.2147/CEOR.S584774","DOIUrl":"10.2147/CEOR.S584774","url":null,"abstract":"<p><strong>Background: </strong>Real-world data on healthcare resource utilization (HCRU) and costs in light chain amyloidosis (AL) by disease severity are limited. This study evaluates HCRU and costs among patients with AL, particularly those with advanced stages.</p><p><strong>Methods: </strong>A retrospective analysis of deidentified patient records (January 2016 to March 2022) from Optum's clinical electronic health record (EHR) database was conducted. Adult patients with ≥2 AL diagnoses or positive mentions of the disease in the physician's notes (≥30 days apart) were included. Patients with a Mayo disease stage, including those with advanced disease (stages IIIa/IIIb), based on cardiac biomarkers (N-terminal pro-brain natriuretic peptide and troponin T), were identified most proximal to the index date (first-identified AL diagnosis date). Patient records were then linked to payer-agnostic claims. Data, including HCRU and costs, were assessed from the index date until the end of continuous enrollment or death (minimum 30-day follow-up) during the 12-month postindex period.</p><p><strong>Results: </strong>Among the 85 patients (75% aged ≥60 years; 65% males) included in the study, 60% had at least one condition-related inpatient hospitalization (66.7% with advanced cardiac involvement), 92.9% had an outpatient visit (54.4% with advanced cardiac involvement), 74.1% had an office visit (53.9% with advanced cardiac involvement), and 22.4% had an emergency room visit (68.4% with advanced cardiac involvement) within 12 months after diagnosis. The median (range) per-patient per-month (PPPM) condition-related total, medical, and drug costs for patients with advanced cardiac involvement (n = 47) were $7532 ($3336-$15,097), $2107 ($1079-$4618), and $4613 ($1664-$9488), respectively. The median (range) PPPM condition-related inpatient hospitalization costs for patients with advanced cardiac involvement (n = 34) was $462 ($77-$1839).</p><p><strong>Conclusion: </strong>This EHR-claims linked database study showed that patients with advanced disease face high economic burden, supporting the continued need for therapeutic advances to help manage this population.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"584774"},"PeriodicalIF":2.6,"publicationDate":"2026-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13150554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147869854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}